Industry Outlook

The solid tumor cancer treatment market is set to reach from US$ 121.3 Bn in 2018 to US$ 424.6 Bn by 2027 at a compound annual growth rate (CAGR) of 15.0% during the forecast period from 2019 to 2027. According to the latest statistics presented by the World Health Organization (WHO) in 2018, approximately 9.6 million people are estimated to die due to cancer; they also claim that 30 to 50% of cancer can be prevented with early diagnosis and effective treatment regimen.

"Hormonal imbalance and unhealthy lifestyle increases the risk of breast cancer in women population worldwide"

Breast cancer is currently leading the indication segment for solid tumor cancer treatment market. The key parameters responsible for its high prevalence rate in women population worldwide are hormonal imbalance during the menstrual cycle of women, unhealthy lifestyle, low or no breast feeding during lifetime. The prevalence rate of lung cancer has seen substantial rise in the last 2 decades owing to increasing number of cigarette smokers globally and significant rise in air pollution.

"Availability of generic version at affordable cost makes chemotherapy popular in cancer treatment"

Chemotherapy is presently the largest therapy segment for solid tumor cancer treatment market. The major factor which makes it popular in cancer treatment is its availability of generic version at affordable cost. They are used in combination to gain excellent results in solid tumor cancer treatment. Biologics such as immunotherapy and targeted therapy have gained tremendous popularity in the solid tumor cancer treatment in a span of 2 decades. Minimal side effects, excellent therapeutic efficacy and favorable reimbursement scenario drives its market growth for treatment of solid tumor cancers.

"Rising prevalence of cancer and domicile of key players together drive the market growth in North America region"

North America is currently representing 33.6% market share in the regional segment for solid tumor cancer treatment market. The primary factor responsible for its market dominance is rising prevalence of cancer, According to the latest statistics brought forward by the Center for Disease Control and Prevention (CDC), in a span of 10 years from 2010-2020 in the U.S. the number of new cancer cases will rise by 24% in men amounting to 1million cases annually and 21% in women approximately 900,000 cases per year. Domicile of major players such as AstraZeneca, Merck & Co., Inc., Amgen, Inc. etc. will further bolster the market growth in the region. Europe accounts for 30.2% market share on account of supportive regulatory environment provided by European Medical Agency (EMA) for the development and sale of pharmacological medicines used in solid tumor cancer treatment. Favorable reimbursement scenario further consolidates the market growth. Asia Pacific with a share of 19.5% will be registering good growth during the forecast period owing to the rising public health awareness regarding cancer and its treatment and developing healthcare infrastructure.

Pharmaceutical companies spearheading the solid tumor cancer treatment market are AstraZeneca, Plc., Amgen, Inc., B. Braun Melsungen AG, Bristol Myers Squibb & Company, Eli Lilly & Company, F.Hoffman La-Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer, Inc. and Olympus Medical Systems.

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Solid Tumor Cancer Treatment market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Solid Tumor Cancer Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Solid Tumor Cancer Treatment market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2032.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Solid Tumor Cancer Treatment market?
• Which is the largest regional market for Solid Tumor Cancer Treatment market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Solid Tumor Cancer Treatment market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Solid Tumor Cancer Treatment market worldwide?